Clinical trials: HSP
Multiple Myeloma
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
- Trial name
- TIME-2 (NCT00514371)
- Testing
- tanespimycin, Bortezomib
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Bristol-Myers Squibb
Advanced Breast Cancer, Treatment-Refractory Solid Tumors
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: Patients with advanced breast cancer that has become worse after taking palbociclib alone Patients with…
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC
- Trial name
- NCT05655598
- Testing
- Palbociclib Oral Product, TAS-116
- Where
- United States
- Sponsor
- Brown University
Aging
Acute Passive Heating in Healthy Older Adults
Aging is associated with a decline in cardiovascular health, cognitive function and losses in muscle strength, with half or more of those over age 65 suffering from two or more comorbidities (e.g., heart disease, type 2…
- Trial name
- NCT05622747
- Testing
- Passive heating
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Portsmouth
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
- Trial name
- NCT00054041
- Testing
- HspE7, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Breast Cancer, Male Breast Cancer
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast…
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT02060253
- Testing
- ganetespib, paclitaxel, trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent soft tissue sarcoma.
- Trial name
- NCT00005628
- Testing
- vitespen
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Henoch-Schoenlein Purpura
The Research of Standard Diagnosis and Treatment for Severe HSP in Children
This study is performed to evaluate the efficacy and safety of various measures in the treatment of severe HSP in children.
- Trial name
- NCT02540720
- Testing
- Dexamethasone, Gamma globulin, Hemoperfusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Children's Hospital
Neoplasms
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist.
- Trial name
- NCT00487786
- Testing
- OGX-427, Docetaxel
- Where
- 3 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Achieve Life Sciences
Venous Thromboembolism (VTE), Acute Myocardial Infarction With ST Segment Elevation
Heat Shock Protein 47 in Thrombosis
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial…
- Conditions
- Venous Thromboembolism (VTE), Acute Myocardial Infarction With ST Segment Elevation, Stroke (in Patients With Atrial Fibrillation)
- Trial name
- NCT06731673
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Recurrent Glioblastoma, Recurrent Adult Brain Tumor
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery.
- Conditions
- Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
- Trial name
- NCT01814813
- Testing
- HSPPC-96, bevacizumab
- Where
- 417 sites in United States
- Volunteers
- 90 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.
- Trial name
- NCT00627627
- Testing
- IPI-504
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Malignant Melanoma
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery…
- Trial name
- NCT00039000
- Testing
- HSPPC-96 or Oncophage
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 350 people
- Sponsor
- Agenus Inc.
Melanoma Stage IV, Sarcoma
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.
- Conditions
- Melanoma Stage IV, Sarcoma, Squamous Cell Carcinoma, Pancreatic Cancer Stage IV
- Trial name
- HSP70CTC (NCT04628806)
- Testing
- CTC isolation by HSP70
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Charite University, Berlin, Germany